Millipore® CTDMO Services delivers expertise and flexible solutions for viral vector development and manufacturing to advance cell and gene therapies from preclinical through commercial production.
Our proficiency with adeno-associated virus (AAV), lentivirus, adenovirus, and other vectors helps streamline the development and manufacturing of cell and gene therapies. From early preclinical through clinical and commercial manufacturing, we offer the comprehensive resources, capabilities, and know-how to advance current and future cell and gene therapies to market.
Our track record includes successful regulatory inspections by the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, the Australian Therapeutic Goods Administration (TGA), and the Brazilian Health Regulatory Agency (ANVISA).
Our viral vector experts work with our clients to identify and evaluate improvements to current processes in order to streamline therapeutic production, address risk, and accelerate cell and gene therapies to the clinic. Through our Manufacturability Assessment, we:
Our experienced Process Development teams incorporate a virus-specific and holistic approach to develop robust and optimized processes to support preclinical through commercial needs.
Our Analytical Development services are tailored to support the success of cell and gene therapies with individualized phase-appropriate testing and support.
Our flexible operations and capacity support clinical through commercial GMP manufacturing for cell and gene therapies.
To streamline cell or gene therapies to market, we offer on-site clinical and commercial fill/finish services, as a continuation of GMP manufacturing.
Throughout the cell and gene therapy development and manufacturing lifecycle, we leverage the same expertise that has seen us through inspections by global regulatory agencies – 6 and counting – to provide dedicated and customized support for regulatory filings, inspections, and responses.
We are dedicated to accelerating viral vector development and manufacturing. Through our de-risked, streamlined, and optimized upstream and downstream platforms, we can seamlessly and robustly scale-up to clinical and commercial manufacturing, while improving overall yield and quality.
We have significant experience in AAV development and manufacturing to quickly progress cell and gene therapy programs.
With over 300 batches produced, we have extensive lentivirus development and manufacturing experience for cell and gene therapies.
Our teams have been developing and manufacturing adenoviral vectors for over 25 years. This deep expertise allows us to efficiently support cell and gene therapy needs.
Leverage our diverse viral vector expertise and experience working with a range of alternative viral vectors, such as reovirus and more, and are open to working with other distinctive viral vectors. Contact us to explore our capabilities and discuss your needs.
We are a single organization with a global network to deliver CDMO services across all stages of the molecule value chain. Our recently expanded viral vector CDMO campus in Carlsbad, California, USA increases production capacity and allows us to provide end-to-end solutions for viral cell and gene therapies in a single facility.
Offering end-to-end viral vector services, our 157,000 sq. ft. state-of-the-art facilities house upstream and downstream production suites, along with fill/finish, warehousing, QC labs, in addition to process and analytical labs to support early phase development to commercial manufacturing of suspension and adherent-based cell and gene therapy platforms.
To continue reading please sign in or create an account.Don't Have An Account?